Photo of ACG Guidelines

safety data

Trulance established safety and tolerability across 2 indications1

Photo of ACG Guidelines

Trulance established safety and tolerability across two indications1

Studied in more than 3100 patients across 4 double-blind, placebo-controlled, 12-week studies.

Treatment-emergent diarrhea was observed in ≤5% of patients

No additional adverse events (AEs) occurred at an incidence of ≥2% in patients treated with Trulance and at an incidence greater than placebo1

Most common AEs in IBS-C1

IBS-C

AE

Trulance 3 mg
(n=723)
Placebo
(n=726)

Diarrhea

4.3%
1%

Severe diarrhea was reported in 1% of patients receiving Trulance vs 0.1% of placebo-treated patients

2.5% discontinuation rate for Trulance vs 0.4% for placebo due to AEs

1.2% discontinuation rate due to diarrhea vs 0% for placebo

Reported in at least 2% of Trulance-treated patients with IBS-C and at an incidence greater than placebo1

Most common AEs in CIC1

CIC

AE

Trulance 3 mg
(n=863)
Placebo
(n=870)

Diarrhea

5%
1%

Severe diarrhea was reported in 0.6% of patients receiving Trulance vs 0.3% of placebo-treated patients

4% discontinuation rate for Trulance vs 2% for placebo due to AEs

2% discontinuation rate due to diarrhea vs 0.5% for placebo

Reported in at least 2% of Trulance-treated patients with CIC and at an incidence greater than placebo1

severediarrhea

If severe diarrhea occurs, suspend dosing and rehydrate the patient1

safetydata-px-nodrug

No drug-drug interactions observed1

minimallyabsorbed

Minimally absorbed with negligible systemic availability1

To see how Trulance works inside the body, watch the MOA video
See More

Indication

Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

Trulance® is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice, administration of a single oral dose of plecanatide caused deaths due to dehydration. Avoid use of TRULANCE in patients 6 years to less than 18 years of age. The safety and effectiveness of TRULANCE have not been established in patients less than 18 years of age.

See Less

Indication

Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

Trulance® is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice, administration of a single oral dose of plecanatide caused deaths due to dehydration. Avoid use of TRULANCE in patients 6 years to less than 18 years of age. The safety and effectiveness of TRULANCE have not been established in patients less than 18 years of age.

Contraindications

  • Trulance is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • Trulance is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

Risk of Serious Dehydration in Pediatric Patients

  • Trulance is contraindicated in patients less than 6 years of age. The safety and effectiveness of Trulance in patients less than 18 years of age have not been established. In young juvenile mice (human age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid secretion into the intestines as a consequence of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than older patients to develop severe diarrhea and its potentially serious consequences.
  • Avoid the use of TRULANCE in patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young mice and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of TRULANCE in patients 6 years to less than 18 years of age.

Diarrhea

  • Diarrhea was the most common adverse reaction in the four placebo-controlled clinical trials for CIC and IBS-C. Severe diarrhea was reported in 0.6% of Trulance-treated CIC patients, and in 1% of Trulance-treated IBS-C patients.
  • If severe diarrhea occurs, suspend dosing and rehydrate the patient.

Adverse Reactions

  • In the two combined CIC clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (5% vs 1% placebo).
  • In the two combined IBS-C clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (4.3% vs 1% placebo).

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please click here for full Prescribing Information for Trulance, including BOXED WARNING.

TRU.0042.USA.24